Making a statistically valid conclusion of the superiority of a clinical intervention in a clinical trial requires not only a statistically significant P value, but also adequate a priori power and an observed effect size larger than the clinically important value specified in the sample size calculation. We scrutinised the five most highly cited clinical trials reporting one or more conclusions of clinical superiority published in Anesthesiology, the British Journal of Anaesthesia, Anaesthesia, Anesthesia and Analgesia and Anaesthesia and Intensive Care in 2011 or 2012 to determine how many met all three requisite criteria. In the 25 articles, there were a total of 36 unconditional conclusions of the superiority of a clinical intervention. All were supported by a statistically significant P value. However, only 15 (41.6%) met all three requisite statistical criteria to support clinical superiority. The remainder included secondary outcomes without specific reference to their observational nature, and primary outcomes whose observed effect size was smaller than the clinically important value specified in the sample size calculation. These findings indicate that clinicians should closely scrutinise conclusions of clinical superiority in anaesthesia journals. Many will be 'hypothesis-generating observations' without adequate statistical support for a conclusion of clinical superiority in their own right.
Valid hypothesis testing in a clinical trial requires an a priori hypothesis, pre-specification of the acceptable α and β errors and a sample size large enough to provide sufficient power (1β) to detect a clinically important (worthwhile, meaningful) difference, should it exist [1] [2] [3] . Under these circumstances, if the P value is statistically significant (P < α), and the observed difference is larger than the clinically important difference specified in the sample size calculation, there is robust support for a conclusion of the superiority of the intervention.
In practice, this degree of statistical rigour is reserved mostly for primary outcomes. For secondary or subgroup outcomes there is typically no power or sample size calculation or pre-specification of the minimum difference that would be considered clinically important. Statistically significant findings under these circumstances may be of interest, but cannot be considered valid conclusions in their own right. They are 'hypothesis-generating observations' rather than 'hypothesis-supporting conclusions'. Hypothesis-generating observations may be important and may represent real differences, but may also be only chance findings, so would require confirmation in subsequent trials.
Another scenario that does not support a conclusion of clinical superiority, despite statistical significance, is an observed effect size smaller than the clinically important effect size specified in the power/ sample size calculation 4 . In this situation, the a priori power no longer applies 5 and the finding does not have the same robustness as an observed difference larger than the pre-specified clinically important difference. Once again, such findings may be of interest and be 'hypothesis-generating'. However, they cannot be considered valid conclusions of clinical superiority in their own right.
It was our impression that many conclusions of clinical superiority in anaesthesia journals did not meet the requisite criteria for statistical validity and were hypothesis-generating rather than hypothesissupporting. The aim of this study was to audit a sample of clinical trials published recently in a range of anaesthesia journals to estimate the current prevalence of conclusions of clinical superiority in anaesthesia research made without adequate statistical support.
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Anaesthesia and Intensive Care, Vol. 42, No. 5, September 2014 (Anesthesiology, British Journal of Anaesthesia, Anaesthesia, Anesthesia and Analgesia, Anaesthesia and Intensive Care) reporting one or more unconditional conclusions of the superiority of a clinical intervention were identified using the Thomson Reuters Web of Science (formally ISI Web of Knowledge) 6 . To be considered unconditional, the conclusion had to appear in the conclusion (or concluding) section of both the abstract and the main text and be definite and unambiguous. Results (whether primary or secondary) that did not appear in these sections were not considered conclusions. Trials in which the conclusions of clinical superiority were indefinite were excluded (e.g. trials reporting 'possible' or 'potential' clinical superiority, those indicating more work was required to confirm their findings and those explicitly reporting their findings as a secondary outcome or as an observation). Equivalence and non-inferiority trials, clinical trials reporting pilot studies and trials reporting predominantly negative findings (i.e. no clinical superiority) were excluded.
Each conclusion of clinical superiority for each trial was then scrutinised for the P value on which it was based, the point estimate of the observed effect size of the variable in question, the a priori power and the a priori definition of the clinically important effect size used in the sample size calculation. If conclusions related to repeated measures (e.g. serial pain scores), only a single indicative P value with its associated point estimate for each conclusion was assessed.
The conclusions were categorised into those that were based on primary outcomes and those that were based on secondary outcomes. Outcomes were considered primary if the sample size calculation was based on this outcome, irrespective of the primary outcome specified by the authors. If no sample size calculation or power calculation was presented, the primary outcome was taken as that specified by the authors.
A conclusion was considered statistically valid if the P value was < α, the observed effect size was ≥ the clinically important effect size specified in the sample size calculation and the power was ≥ 0.8 (80%). Conclusions that were supported by a P value < α but were not supported by the other requisite criteria were considered 'hypothesis-generating observations'.
For the purposes of the audit all other aspects of the methodology were assumed to be valid.
RESULTS
In the 25 articles scrutinised, there were a total of 36 unconditional conclusions of the superiority of a clinical intervention (Tables 1 to 5 and Figure 1 All were supported by a statistically significant P value (P < α). However, only 15 (41.6%) met the other two requisite criteria for statistical validity (power ≥ 80%, observed effect size ≥ the clinically important effect size specified in the sample size calculation). Of the remaining 21 conclusions, eight were related to primary outcomes and 13 to secondary outcomes. Six of the eight primary outcomes had an observed effect size < the clinically important effect size specified in their sample size calculation; two did not specify a clinically important effect size. Seven of the secondary outcome conclusions were associated with positive primary outcomes and six with negative primary outcomes.
DISCUSSION
The results of this audit indicate that there are many conclusions of clinical superiority in highly cited articles published recently in anaesthesia journals that do not meet the requisite criteria for statistical validity. Although all 36 conclusions in the 25 articles were supported by a statistically significant P value, only 15 reported both adequate a priori power and an observed effect size larger than the clinically important value specified in the sample size calculation (Tables 1 to 5 and Figure 1 ). The remaining conclusions were more correctly 'hypothesis-generating observations'. These 'hypothesis-generating observations' may be important, and may warrant further investigation in subsequent trials, but are not valid conclusions in their own right.
The caveat to avoid making conclusions of the clinical superiority of an intervention on the basis of a P value alone, without considering the a priori power and the observed effect size, appears consistently in anaesthesia textbooks 1-3 and journal articles 4,32-36 and is in the Consolidated standards of reporting trials (CONSORT) statement 37 . This is because P values tell us little about the replicability of a finding or its clinical importance 5, 38 . P values tell us the probability of obtaining the observed result or one more extreme given that the null hypothesis is true 1 . In a hypothesis test, if the P value is < α (e.g. < 0.05), then the null hypothesis is rejected 1 . However, the P value, and even the statistical significance of the result, applies only to the study undertaken. It does not necessarily apply to repeats of the same study, even if the same sampling criteria are used 5, 36 . Only if the P value is extremely low does it support replication of statistical significance in repeat studies 5, 38 . In contrast, the a priori power tells us 'the probability of rejecting the null hypothesis given that it is false' 1 each time the same study is undertaken (although for two-tailed 
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Conclusions supported by all three requisite criteria are highlighted. PONV=postoperative nausea and vomiting. LMA=laryngeal mask airway. tests the direction of the result is not specified). In other words, the a priori power informs us about the likelihood of replicating the statistically significant result. It is difficult to conclude that an intervention is clinically superior if it is unlikely to be statistically significant in repeat studies or if the replicability is unknown.
As secondary and subgroup outcomes typically have no power calculation, they cannot support a conclusion of clinical superiority in their own right, even if they have a statistically significant P value.
Yet, in our audit there were 13 conclusions of clinical superiority related to secondary outcomes. None of these alluded to the observational nature of these outcomes. It could be argued that the observational nature of secondary outcomes is implicit. Nevertheless, readers may find it difficult to discriminate between primary and secondary outcome conclusions if this is not made explicit by the authors. Unless it is explicit, there is always a risk that the observational nature of secondary outcome conclusions might be missed. This is especially so if secondary outcome conclusions are included in the title of the paper, as was the case in two papers in our audit 12, 31 .
It could be supposed that the power provided for primary outcome comparisons automatically applies to secondary outcomes. However, each comparison requires its own power calculation, with its own clinically important effect size, α error and sample variability 39, 40 . Also, post-hoc calculations of power are not meaningful 39, 40 .
In a clinical trial the clinically important effect size or difference is the magnitude of difference that the authors wish to detect (should a difference of this magnitude exist). It is typically based on the magnitude of difference that would justify a change in clinical practice. In order to reliably detect all possible magnitudes of clinically important difference it is necessary to base the sample size on the 'minimum' clinically important value. This is because the minimum clinically important value is still clinically important (i.e. would still justify a change in clinical practice). Choosing a larger value would reduce the required sample size, thereby reducing the power to detect the subset of differences between the minimum clinically important difference and the value chosen. Choosing a smaller value would increase the required sample size, which would involve randomising more patients than necessary to answer the clinical question. For these reasons, the clinically important difference entered in the sample size calculation should be the most accurate estimate of the true 'minimum' clinically important difference available. While this is not a requirement for hypothesis testing, sample size estimates based on values other than the minimum clinically important difference are less than ideal.
If an observed effect size is less than the authors' own pre-defined 'minimum' clinically important value, by definition the difference is too small to be clinically important. A conclusion of clinical superiority in this situation cannot be supported, either logically or statistically. This was the case in six of the primary outcome conclusions in our audit. In some cases the observed effect size was only slightly less than the pre-defined clinically important value 9 . However, in others the observed effect size was substantially less (e.g. two-thirds or less) than the clinically important 25 RCTs with one of more unconditional conclusions of clinical superiority 36 11, 14, 15, 17 . In two cases the clinically important value was not specified 24,29 making it impossible for readers to fully assess the statistical validity of the conclusion. It could be misconstrued that the clinically important difference is only an arbitrary value that has no relevance once a study is completed. However, the clinically important difference is not arbitrary insofar as it determines the requisite sample size for any given level of power. Reducing the clinically important difference post hoc (claiming that a smaller difference is clinically important), without changing the sample size accordingly, increases the β error and thereby reduces the power 4, 5 . With reduced power, there is less robust support for a conclusion of clinical superiority.
When assessing observed effect sizes it could be argued that the 95% confidence interval (CI) should be scrutinised rather than the point estimate alone. However, while the 95% CIs include effect sizes larger than the point estimate they also include an equal number and magnitude of smaller effect sizes. In any event, the true effect size is more likely to be closer to the point estimate than to the extremes of the CI. For this reason, we considered only the point estimates in this audit.
It is often recommended that the 95% CIs for observed differences be presented instead of P values, because CIs add information on the range of likely true effect sizes. However, CIs do not provide information on whether the sample size is adequate for any specified level of power. There are CI approaches to determining sample sizes required to reliably detect pre-defined clinically important differences (should they exist), but they are rarely used 41 . These approaches involve pre-defining an acceptable CI width and then assessing whether the observed CI is within this width 41 . None of the trials in the current study took this approach.
We do not contend that meeting the three criteria of statistical significance, an observed effect size ≥ a pre-defined clinically important value and adequate power together constitute 'sufficient conditions' for a valid conclusion. There are many other aspects of clinical trials that require detailed scrutiny before their conclusions can be assessed as valid. These are outside the scope of our study, but are well summarised in the CONSORT statement and checklist 37 . Similarly, the validity of conclusions should be considered in the light of previous experience. Nevertheless, we contend that all three are 'necessary conditions', and that if one or more is missing, then a conclusion of clinical superiority cannot be fully supported, no matter how valid other aspects of the clinical trial might be.
We also do not contend that readers should accept authors' definitions of 'clinically important effect sizes' without question. Readers should make their own judgement about whether the value specified is a true 'minimum' clinically important effect size. The value specified might be too small; this may occur in multicentre trials involving a large number of patients, in which case statistical significance may be found despite a clinically unimportant difference 42 . Alternatively, the value may be too large, in which case smaller differences would be worthy of further investigation; this would be particularly important in negative studies. We contend, however, that authors should not question their own pre-defined clinically important effect size.
We chose to investigate clinical trials in Anesthesiology, the British Journal of Anaesthesia, Anaesthesia, Anesthesia and Analgesia and Anaesthesia and Intensive Care, because the first four are the highest ranked by impact factor 6 non-subspecialty anaesthesia journals, and Anaesthesia and Intensive Care is likely to be familiar to most Australian and New Zealand anaesthetists. We chose the five most highly cited trials for the study period for each journal, on the basis that these would most likely have as sound, if not more sound, statistical validity than any other trials published recently in these journals. We found examples of conclusions of clinical superiority without adequate statistical validity in all five journals. We anticipate that we would obtain similar findings in most if not all anaesthesia journals.
A major limitation of this audit is that it is observational itself. Moreover, the sample size was small. Nevertheless, the observed effect size (58.4% of conclusions of clinical superiority lacked statistical validity) is compelling. This magnitude of effect size, if true, should be easy to reproduce. We invite readers to scrutinise any sample of clinical trial conclusions of superiority to check this finding.
Misinterpreting hypothesis-generating observations for valid conclusions could result in an inappropriate change to clinical practice. For this reason, clinicians should carefully scrutinise the power calculations, observed effect sizes and clinically important effect sizes of clinical trials before accepting conclusions of clinical superiority. Authors should also be encouraged to clearly discriminate between valid conclusions and hypothesis-generating observations when presenting their findings.
